Trial · NCT00739141
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
NCT00739141, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2022-12-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. Trials, record NCT00739141. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00739141
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
- NCT number
- NCT00739141
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 86 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma, Chronic Myelogenous Leukemia, Hodgkins Lymphoma
- Interventions
- fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
- First posted
- 2008-08-21
- Last updated
- 2022-12-08
- Results first posted
- 2022-12-08
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival/PFS at 1 Year Post UCBT. | 1 year post UCBT | To obtain a preliminary estimate of progression free survival at 1 year post UCBT. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Secondary | Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients | up to 13 days from engraftment | Successful primary donor engraftment = neutrophill recovery within the first 45 days after transplant and partial/complete donor chimerism (\>/= 10%) |
| Secondary | Percentage of Participants With Sustained CB-derived Neutrophil Engraftment | 100 days | The day 100 cumulative incidence of sustained CB-derived neutrophil engraftment. |
| Secondary | Percentage of Participants With Sustained CB-derived Platelet Engraftment | 100 days | The day 100 cumulative incidence of sustained CB-derived platelet engraftment to \>/= 20 x 10\^9/L |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival/PFS at 1 Year Post UCBT. | 1 year post UCBT | percentage of participants | NUMBER | |
| SECONDARY | Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients | up to 13 days from engraftment | 43 haplo-dCBT recipients in this analysis 43 dCBT recipient | participants | NUMBER |
| SECONDARY | Percentage of Participants With Sustained CB-derived Neutrophil Engraftment | 100 days | Percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants With Sustained CB-derived Platelet Engraftment | 100 days | Percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival/PFS at 1 Year Post UCBT. | Participants With Hematologic Malignancies | 84 | 95% Confidence Interval 77 to 92 | percentage of participants | |
| Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients | Participants With Hematologic Malignancies | Haplo-dCBT with early haplo-derived myeloid bridge | 17 | participants | |
| Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients | Participants With Hematologic Malignancies | Haplo-dCBT with transient haplo-derived bridge with second neutrophil nadir | 13 | participants | |
| Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients | Participants With Hematologic Malignancies | Haplo-dCBT with no bridge | 13 | participants | |
| Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients | Participants With Hematologic Malignancies | Remaining dCBT recipient | 43 | participants | |
| Percentage of Participants With Sustained CB-derived Neutrophil Engraftment | Participants With Hematologic Malignancies | 99 | 95% Confidence Interval 87 to 99 | Percentage of participants | |
| Percentage of Participants With Sustained CB-derived Platelet Engraftment | Participants With Hematologic Malignancies | 93 | 95% Confidence Interval 85 to 97 | Percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants With Hematologic Malignancies | 86 | |
| Overall Study | COMPLETED | Participants With Hematologic Malignancies | 81 | |
| Overall Study | NOT COMPLETED | Participants With Hematologic Malignancies | 5 |
Source ClinicalTrials.gov
Adverse events43
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Investigations | Participants With Hematologic Malignancies | 20 | 86 | |
| other | AST, SGOT | Investigations | Participants With Hematologic Malignancies | 9 | 86 | |
| other | Alkaline phosphatase | Investigations | Participants With Hematologic Malignancies | 6 | 86 | |
| other | Bilirubin (hyperbilirubinemia) | Investigations | Participants With Hematologic Malignancies | 37 | 86 | |
| other | Creatinine | Investigations | Participants With Hematologic Malignancies | 7 | 86 | |
| other | Glucose, high (hyperglycemia) | Metabolism and nutrition disorders | Participants With Hematologic Malignancies | 47 | 86 | |
| other | Magnesium, high (hypermagnesemia) | Metabolism and nutrition disorders | Participants With Hematologic Malignancies | 26 | 86 | |
| serious | Anorexia | Metabolism and nutrition disorders | Participants With Hematologic Malignancies | 2 | 86 | |
| serious | Aspiration | Respiratory, thoracic and mediastinal disorders | Participants With Hematologic Malignancies | 1 | 86 | |
| serious | Blood/Bone Marrow, other | Blood and lymphatic system disorders | Participants With Hematologic Malignancies | 1 | 86 |
1 to 10 of 43Source ClinicalTrials.gov
See all 43 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants With Hematologic Malignancies | 36 | 86 |
| Total, other adverse events | Participants With Hematologic Malignancies | 47 | 86 |
| Total, serious adverse events | Participants With Hematologic Malignancies | 41 | 86 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23416850 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00739141
GET https://conductscience.org/api/trials/v1/NCT00739141/events?page=2